179 related articles for article (PubMed ID: 34923887)
1. 2-Arylquinolines as novel anticancer agents with dual EGFR/FAK kinase inhibitory activity: synthesis, biological evaluation, and molecular modelling insights.
Elbadawi MM; Eldehna WM; Abd El-Hafeez AA; Somaa WR; Albohy A; Al-Rashood ST; Agama KK; Elkaeed EB; Ghosh P; Pommier Y; Abe M
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):349-372. PubMed ID: 34923887
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Zou M; Li J; Jin B; Wang M; Chen H; Zhang Z; Zhang C; Zhao Z; Zheng L
Bioorg Chem; 2021 Sep; 114():105200. PubMed ID: 34375195
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel series of substituted quinolines acting as anticancer agents and selective EGFR blocker: Molecular docking study.
Kumar CBP; Raghu MS; Prathibha BS; Prashanth MK; Kanthimathi G; Kumar KY; Parashuram L; Alharthi FA
Bioorg Med Chem Lett; 2021 Jul; 44():128118. PubMed ID: 34015505
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and anti-proliferative activity of some new quinoline based 4,5-dihydropyrazoles and their thiazole hybrids as EGFR inhibitors.
George RF; Samir EM; Abdelhamed MN; Abdel-Aziz HA; Abbas SE
Bioorg Chem; 2019 Mar; 83():186-197. PubMed ID: 30380447
[TBL] [Abstract][Full Text] [Related]
5. A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
Mustafa M; Abd El-Hafeez AA; Abdelhamid D; Katkar GD; Mostafa YA; Ghosh P; Hayallah AM; Abuo-Rahma GEA
Eur J Med Chem; 2021 Oct; 222():113569. PubMed ID: 34111829
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of novel covalent inhibitors targeting focal adhesion kinase.
Chen T; Liu Y; Shi M; Tang M; Si W; Yuan X; Wen Y; Chen L
Bioorg Med Chem Lett; 2021 Dec; 54():128433. PubMed ID: 34757216
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of novel quinoline/chalcone/1,2,4-triazole hybrids as potent antiproliferative agent targeting EGFR and BRAF
Mohassab AM; Hassan HA; Abdelhamid D; Gouda AM; Youssif BGM; Tateishi H; Fujita M; Otsuka M; Abdel-Aziz M
Bioorg Chem; 2021 Jan; 106():104510. PubMed ID: 33279248
[TBL] [Abstract][Full Text] [Related]
8. Free energy perturbation guided Synthesis with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).
Karnik KS; Sarkate AP; Tiwari SV; Azad R; Wakte PS
Bioorg Chem; 2021 Oct; 115():105226. PubMed ID: 34364055
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of 2,4-diamino pyrimidine derivatives as potent FAK inhibitors with anti-cancer and anti-angiogenesis activities.
Wang S; Zhang RH; Zhang H; Wang YC; Yang D; Zhao YL; Yan GY; Xu GB; Guan HY; Zhou YH; Cui DB; Liu T; Li YJ; Liao SG; Zhou M
Eur J Med Chem; 2021 Oct; 222():113573. PubMed ID: 34091209
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
Shaheen MA; El-Emam AA; El-Gohary NS
Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
13. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
Lamie PF; El-Kalaawy AM; Abdel Latif NS; Rashed LA; Philoppes JN
Eur J Med Chem; 2021 Mar; 214():113222. PubMed ID: 33545637
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 4-alkoxy-2-aryl-6,7-dimethoxyquinolines as a new class of topoisomerase I inhibitors endowed with potent in vitro anticancer activity.
Elbadawi MM; Eldehna WM; Wang W; Agama KK; Pommier Y; Abe M
Eur J Med Chem; 2021 Apr; 215():113261. PubMed ID: 33631697
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858
[TBL] [Abstract][Full Text] [Related]
16. Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity.
Ibrahim DA; Abou El Ella DA; El-Motwally AM; Aly RM
Eur J Med Chem; 2015 Sep; 102():115-31. PubMed ID: 26256032
[TBL] [Abstract][Full Text] [Related]
17. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
El-Sayed NA; Nour MS; Salem MA; Arafa RK
Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors.
Altıntop MD; Sever B; Akalın Çiftçi G; Turan-Zitouni G; Kaplancıklı ZA; Özdemir A
Eur J Med Chem; 2018 Jul; 155():905-924. PubMed ID: 29966916
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and molecular modeling of biquinoline-pyridine hybrids as a new class of potential EGFR and HER-2 kinase inhibitors.
Sangani CB; Makawana JA; Duan YT; Yin Y; Teraiya SB; Thumar NJ; Zhu HL
Bioorg Med Chem Lett; 2014 Sep; 24(18):4472-4476. PubMed ID: 25172421
[TBL] [Abstract][Full Text] [Related]
20. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
